Endometriosis drugmaker Meditrina Pharmaceuticals wants to raise $500,000, according to a regulatory filing.
Meditrina, which is based in Ann Arbor, Michigan, is using patents from AstraZeneca to treat women’s health problems including endometriosis and uterine fibroids, which are abnormal growths or tumors that can cause pain and infertility. The company has completed Phase II trials on its two drugs – MPI-676 and MPI-674 – which treat endometriosis and abnormal uterine bleeding, respectively.
Its drugs stop the creation of aromatase, which typically creates estrogen.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The four-year-old company launched with about $4.4 million in funding provided through the state of Michigan.
